Biopharma's remarkable rush to address the global health crisis posed by the COVID-19 pandemic, as well as the impact of the virus on bottom lines, will be a central theme the upcoming second quarter sales and earnings reporting season – with investors and the public particularly keen to hear about the trajectory or commercial prospects for treatments or vaccines for COVID-19. But big pharma is a big business, and there are plenty of other updates worth listening for when second quarter earnings kick off on 16 July with Johnson & Johnson.
A new long-term risk for the pharmaceutical industry is looming on the horizon if US unemployment and a corresponding loss...
